Retatrutide vs Tirzepatide: What Actually Separates Them

The core difference: one medicine exists in UK clinical practice; one doesn't

Tirzepatide activates two gut-hormone receptors, GIP and GLP-1, which work together to reduce appetite, slow gastric emptying and improve blood-sugar regulation. It is the only dual-agonist weight-loss medicine with a UK licence, approved for adults with a BMI of 30 or above, or 27 or above alongside a weight-related condition such as high blood pressure or type 2 diabetes. The NICE appraisal of tirzepatide (TA1026) confirmed its clinical and cost-effectiveness for NHS use, and the results from SURMOUNT-1 (around 20–21% average body-weight reduction at the highest dose over 72 weeks) are among the strongest published for any weight-loss medicine. You can read the full NICE recommendation at nice.org.uk/guidance/ta1026.

Retatrutide is a triple agonist, targeting GIP, GLP-1 and glucagon receptors simultaneously. Phase 2 trial data reported weight reductions of around 24% at the highest dose, figures that attracted substantial research interest. Phase 3 trials are ongoing. No regulatory submission has been made to the MHRA, and there is no approved product, licensed dose or legal supply chain in the UK. Any source offering retatrutide today is operating outside the licensed medicines framework. That is the practical reality, and it matters more than any trial headline.

Our page comparing retatrutide and tirzepatide in depth covers the phase 2 data in full; the comparison below focuses on what is verifiable and clinically relevant to a decision you can actually make.

What the evidence shows, side by side

Phase 2 retatrutide figures are preliminary by design. They involve smaller populations, shorter follow-up and optimised conditions that phase 3 trials test against the real world. The ~24% figure is intriguing; it is not yet a reliable basis for clinical decision-making.

The practical factors that actually guide the choice right now

For anyone in the UK making a decision today, the comparison between retatrutide and tirzepatide is not really a head-to-head between two equivalent options. It is a choice between a medicine with a robust evidence base, an established safety record and a legal prescription route, and one that is still in trials.

Tirzepatide's GIP-and-GLP-1 mechanism is well characterised. The common side effects (nausea, loose stools, indigestion, reduced appetite) are GI-led, generally most noticeable in the first few weeks and at each dose step. The NHS medicines page for tirzepatide covers what to expect clearly. Retatrutide's tolerability profile at therapeutic doses remains under evaluation; the glucagon arm of its mechanism may affect lean mass and energy expenditure differently, but this is investigational territory, not settled clinical knowledge.

Cost context is relevant too. Tirzepatide's UK list price rose significantly from September 2025, the highest dose now sits around £330 per four-week pen at list, with private providers typically ranging £149–£375 a month depending on dose and service. Retatrutide has no UK price, because there is no UK product. Our page on the Eli Lilly price increase sets out what changed and why.

If what you're really weighing is whether a different GLP-1 mechanism might suit you better than tirzepatide, that is a conversation worth having with a prescriber. Our broader page on GLP-1 versus tirzepatide explains the mechanistic difference in practical terms.

Which medicine should you choose?

This question has a clear answer for now: retatrutide is not available, so it cannot be chosen. The decision is whether tirzepatide is right for you, and that turns on your BMI, your weight-related health history, any existing medicines you take and other individual factors a prescriber works through with you.

Tirzepatide outperformed semaglutide 2.4 mg (Wegovy) in the SURMOUNT-5 head-to-head trial published in the New England Journal of Medicine in 2025, producing greater average weight loss over 72 weeks. That positions it at the stronger end of what is currently licensed. Whether it is the right starting point for you is not a ranking exercise, it is a clinical assessment. If you'd like to read more about how it compares with other available medicines, the Mounjaro overview and the tirzepatide versus Mounjaro page (the same medicine, two names explained) are good starting points, and if you are also wondering whether the branded and generic names refer to identical treatments, our page comparing tirzepatide and Manjaro addresses that question directly.

When retatrutide reaches the point of regulatory submission and, eventually, approval, the clinical picture will look different. Until then, the prescribers at nume are working with what the evidence and the law currently support. Which treatment suits you is a clinical decision our prescribers make with you, and you can begin that conversation with a free consultation.